Adgero Biopharmaceuticals Holdings, Inc. Note Agreements
10 Contracts & Agreements
- 8% Convertible Note, dated November 26, 2012, among Adgero Biopharmaceuticals, Inc. and Steven Rychnovsky, PhD (Filed With SEC on February 14, 2017)
- 8% Convertible Note, dated November 26, 2012, among Adgero Biopharmaceuticals, Inc. and St. Cloud Investments, LLC (Filed With SEC on February 14, 2017)
- Amendment to 6% Convertible Note, dated March 21, 2016, among Adgero Biopharmaceuticals, Inc. and Adam Stern (Filed With SEC on February 14, 2017)
- 6% Convertible Note, dated December 23, 2015, among Adgero Biopharmaceuticals, Inc. and Adam Stern (Filed With SEC on February 14, 2017)
- Amendment to 6% Convertible Note, dated March 28, 2016, among Adgero Biopharmaceuticals, Inc. and Roman Perez-Soler, MD (Filed With SEC on February 14, 2017)
- 6% Convertible Note, dated October 28, 2015, among Adgero Biopharmaceuticals, Inc. and Roman Perez-Soler, MD (Filed With SEC on February 14, 2017)
- Amendment to 6% Convertible Note, dated March 25, 2016, among Adgero Biopharmaceuticals, Inc. and Robert F. Hendrickson (Filed With SEC on February 14, 2017)
- 6% Convertible Note, dated October 6, 2015, among Adgero Biopharmaceuticals, Inc. and Robert F. Hendrickson (Filed With SEC on February 14, 2017)
- Amendment to Promissory Note, dated December 30, 2015, among Adgero Biopharmaceuticals, Inc. and Frank Pilkiewicz, PhD (Filed With SEC on February 14, 2017)
- Promissory Note, dated July 9, 2014, among Adgero Biopharmaceuticals, Inc. and Frank Pilkiewicz, PhD (Filed With SEC on February 14, 2017)
